A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who Are Resistant or Refractory to T-DM1

Trial Profile

A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who Are Resistant or Refractory to T-DM1

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs DS 8201 (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DESTINY-Breast01
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 19 Oct 2017 Planned End Date changed from 1 Aug 2019 to 1 Feb 2020.
    • 19 Oct 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Feb 2020.
    • 29 Aug 2017 Status changed from not yet recruiting to recruiting as per Daiichi Sankyo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top